New research reveals that patients who stop using popular weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who end traditional diet and exercise plans.
Published data in a leading health publication shows that while overweight individuals often shed substantial amounts of their body weight while using the jabs, the mass is regained at an average rate of 0.8 kg per month after stopping.
"Users using these medications must be cognizant of the potential of fast weight regain when the therapy concludes," warns lead investigator Dr. Susan Jebb.
This pace of regain suggests a reversion to original weight in about 18 months.
Comparing Approaches
The study, which examined 37 of studies involving over 9,000 of participants, contrasted the results of the injectable medications with conventional dieting.
Scientists emphasize that people who shed pounds through diet and exercise usually see a more gradual weight regain—perhaps 0.1 kg a month—after stopping.
The Reason for the Fast Rebound
Doctors suggest the mechanism of the jabs is key to understanding the heightened regain.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of GLP-1 levels far above than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement results in appetite is uncontrolled, making binge eating a significant risk."
An Ongoing Issue?
Medical guidelines suggest the injections for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
A number of clinicians argue that, considering the significant potential of relapse, the treatment should be considered long-term.
This opinion is echoed by drug manufacturers, who note that the results "underscore the long-term nature of obesity," similar to managing diseases like hypertension.
Patient Experiences
People who have discontinued the jabs describe a powerful return of hunger.
"It was like a trigger activating and you become extremely hungry," said a patient.
This difficulty is exacerbated if patients have not developed lasting dietary or behavioural changes during treatment.
Significant Use
Survey data show that millions of people in the UK have used these injections in the last 12 months, with demand continuing to grow.
- Use is greater among women compared to men.
- The middle-aged age group shows the greatest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
Finally, clinicians emphasize that while GLP-1 drugs are potent tools for shedding pounds, they are not a magic fix and lasting health benefits hinges on combined lifestyle support.
